ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs. treatment of physicianʼs choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) - Bardia, A; Tolaney, S M; Loirat, D (Ann Oncol, 2020)